<DOC>
	<DOCNO>NCT00112008</DOCNO>
	<brief_summary>The propose study design test novel dosing paradigm would facilitate treatment anemia CKD patient dialysis . Anemic patient currently receive ESA therapy dose darbepoetin alfa Q2W 18 week .</brief_summary>
	<brief_title>Study Subjects With Chronic Kidney Disease ( CKD ) Not Receiving Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Diagnosis CKD expect initiate dialysis duration study Estimated glomerular filtration rate ( eGFR ) : great equal 15 mL/min less equal 60 mL/min measure follow modify MDRD ( Modification Diet Renal Disease ) equation : eGFR = 186 x [ serum creatinine ] 1.154 x [ Age ] 0.203 x [ 0.742 subject female ] x [ 1.212 subject black ] Clinically stable , judgment investigator Mean Hb great equal 11.0 g/dL less equal 13.0 g/dL ( mean 2 value draw least 3 day apart screen period ) Transferrin saturation ( Tsat ) great equal 15.0 % Serum vitamin B12 folate level low limit normal range Receiving stable Q2W subcutaneous ( SC ) dose AranespÂ® ( darbepoetin alfa ) . A stable dose define less equal 25 % change dose 6week period immediately prior enrollment miss dos period Prior recipient schedule receive kidney transplant Diastolic blood pressure ( BP ) great 110 mm Hg systolic BP great 180 mm Hg screen Acute myocardial ischemia Hospitalization congestive heart failure myocardial infarction within 12 week enrollment Parathyroid hormone level great 1500 pg/mL Major surgery within 12 week enrollment ( exclude vascular access surgery ) Currently receive antibiotic therapy systemic infection Known positive HIV antibody positive hepatitis B surface antigen Clinical evidence current malignancy and/or receive systemic chemotherapy/radiotherapy exception basal cell squamous cell carcinoma skin cervical intraepithelial neoplasia Red blood cell ( RBC ) transfusion within 8 week enrollment Androgen therapy within 8 week enrollment Systemic hematologic disease ( e.g. , sickle cell anemia , myelodysplastic syndrome , hematologic malignancy , myeloma , hemolytic anemia ) Any disorder may impact ( judgment investigator ) ability give inform consent participation study Pregnant breastfeed woman All subject must practice adequate contraception ( judgment investigator ) throughout trial Treatment investigational agent device within 30 day enrollment schedule receive investigational agent specify protocol course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Anemia</keyword>
</DOC>